$LTRN News
Last published 1d ago
- 1d agoLTRNLantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with SpironolactoneBusiness WireDALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, and its wholly owned subsidiary Starlight Therapeutics today announced the publication of Phase 1a clinical data for LP-184 (zirdafulven) in patients with recurrent GBM. LP-184 is being developed as STAR-001 for central nervous system (CNS) cancers. The paper appears in the October 2 ...
- 3w agoLTRNTHE THINKEQUITY CONFERENCE 2026 - LANTERN PHARMA INCEarnings Call TranscriptsHello, everybody. Good evening. I'm going to be introducing Pana from Lantern Pharma here for this presentation. All right. Thank you. Sorry to keep you guys waiting, but let's go ahead and get started. I'm gonna be talk
- 1mo agoLTRNLantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026Business WireLantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform
- 1mo agoLTRNLantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLCBusiness WireThe Taiwan FDA approved the amended protocol and the lead Taiwan site received IRB approval during September of 2026. The next stage (Part 2) is a single-arm study enrolling never-smoker patients with the EGFR exon
- 1mo agoLTRNLantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct OfferingBusiness Wire$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of the warrants Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern", the "Company" or
- 1mo agoLTRNLantern Pharma Inc. Announces up to $8 Million Registered Direct OfferingBusiness Wire$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of the warrants Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern", the "Company" or
- 1mo agoLTRNEarnings Call - LANTERN PHARMA INCEarnings Call TranscriptsGood afternoon everybody. We're going to go ahead and get started on our call and webinar here in a few minutes. We are going to give everyone some time to log in. We're increasing the number of attendees, I've got my co
- 1mo agoLTRNOpen-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ETBusiness WireManagement will also discuss usage patterns, key future milestones, and an overview of the types of collaborations and partnerships under discussionInvestors, collaborators, prospective partners, and interested parties
- 1mo agoLTRNLantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell LymphomasBusiness WireNewly allowed claims provide LP‑284 patent protection into 2042 for the treatment of mantle cell lymphoma and double-hit lymphoma, two blood cancers with high-unmet-needs The U.S. Patent and Trademark Office (USPTO)
- 1mo agoLTRNLantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23Business WireBuilt Inside Active Clinical Programs: A New Generation of AI Co-Scientists Designed to Compress Research Timelines and Expand What Is Possible in Drug Development Open-Medicine AI Founder & CEO Panna Sharma to
- 2mo agoLTRNLantern Pharma | Second Quarter 2026 Operating & Financial Results Conference Call - LANTERN PHARMA INCEarnings Call TranscriptsGood morning and welcome to our second quarter 2026 earnings call. As a reminder, this call is being recorded and all attendees are in a listen-only mode. We will open the call for questions and answers after our managem
- 2mo agoLTRNLantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business UpdateBusiness WireOpen Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EMA Clears LP-184, zirdafulven, for
- 3mo agoLTRNLantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ETBusiness WireWebcast to be held Friday, August 14th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence ("AI") company developing
- 3mo agoLTRNLantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of MedicineBusiness WireThe Open-Medicine AI multi-agentic co-scientist platform represents the strategic evolution of withZeta.ai and is expanding into additional disease areas and modalities. The creation of the new entity, signed
- 3mo agoLTRNLantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder CancerBusiness WireInvestigator-initiated European study will evaluate a distinctive dual-biomarker precision-oncology strategy — PTGR1 overexpression combined with tumor-specific Nucleotide Excision Repair — in patients with advanced
- 3mo agoLTRNLantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor CancersBusiness WireAllowed patent claims cover the use of a three-gene expression signature — PTGR1, PTPN14, and ASPH — to identify patients for treatment with LP-184 (Zirdafulven) In a completed 63-patient Phase 1a trial, LP-184
- 4mo agoLTRNLantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every CancerBusiness WireFirst previewed in the company’s May roadmap, the new withZeta.ai module now enters early access with leading bioinformatics teams and Lantern collaborators — autonomously designing experiments, building rigorous
- 5mo agoLTRNLantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung CancerBusiness WireExon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile. PFS benefit deepens with treatment
- 5mo agoLTRNLantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLCBusiness WireThe FDA raised no objections to Lantern's key proposed protocol amendments to the HARMONIC™ clinical trial. Amendments include: (1) enriching enrollment for patients with EGFR exon 21 L858R mutations; (2)
- 6mo agoLTRNLantern Pharma Reports First Quarter 2026 Financial Results and Provides Business UpdatesBusiness WireDisciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up
- 6mo agoLTRNLantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional InvestorBusiness Wire$4.4 million upfront with up to an additional $4.85 million of potential aggregate gross proceeds upon the exercise in full of the warrants Offering priced at the closing price with unregistered warrants exercisable
- 6mo agoLTRNLantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional InvestorBusiness Wire$4.4 million upfront with up to an additional $4.85 million of potential aggregate gross proceeds upon the exercise in full of the warrants Offering priced at the closing price with unregistered warrants exercisable
- 6mo agoLTRNLantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026Business WireLantern Pharma Inc.
- 6mo agoLTRNLantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™Business WirePlanned additions are designed to expand and enhance withZeta.ai's capabilities, including: real-time, multi-omic computational analyses; simultaneous, highly parallel multi-agentic reasoning, and enterprise-grade
- 6mo agoLTRNLantern Pharma's predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers GloballyBusiness Wire360-Degree Small-Molecule Developability Profiling from a Single SMILES String in Seconds by characterizing and calculating 99 critical molecular features Capabilities are Fully Integrated into withZeta.ai® for
- 6mo agoLTRNLantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific DebutBusiness WireCEO Panna Sharma to Lead Live, Unscripted Platform Walkthrough in Two Interactive Sessions on April 30, 2026 — Open to Investors, Researchers, and the Global Biomedical Community Registration Link & Details Can
- 6mo agoLTRNEmerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added ToxicityBusiness WireLantern Pharma Schedules Type C Meeting with the FDA to Advance HARMONIC™ Protocol Amendments Targeting This High-Need Population, Reflecting LP-300's Novel Mechanism of Action and the Rapidly Evolving Post-TKI
- 7mo agoLTRNLantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22Business WirePlatform Now Available with Introductory, Academic, & Commercial Subscription Tiers Live Debut at Nasdaq MarketSite, New York City — April 16, 2026, 12:00–2:00 PM Eastern Public Demonstrations at AACR 2026,
- 7mo agoLTRNLantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026Business WireBriefing to Feature a Live Walkthrough, Demonstration of Key Features, The Market Opportunity & Industry Need, Competitive Positioning, and Platform Monetization Strategy Lantern Pharma Inc. (NASDAQ:LTRN)
- 7mo agoLTRNLantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesBusiness WireYear of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization, and Global Trial Milestones LP-300 Phase 2 HARMONIC™ Trial Progress: Continued enrollment
- 7mo agoLTRNLantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party ReportBusiness WireLantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), an AI‑driven, clinical‑stage oncology company leveraging its proprietary RADR® platform to transform the cost and timeline of cancer drug development,
- 7mo agoLTRNLantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001Business WireThe Planned Multicenter Phase 1 Trial Will Evaluate STAR-001 as Monotherapy and in Combination with Spironolactone in Children with Relapsed or Refractory CNS Malignancies, Including ATRT, DIPG, GBM, Medulloblastoma,
- 7mo agoLTRNLantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ETBusiness WireWebcast to be held Monday, March 30th, 4:30 p.m.
- 9mo agoAVBPSMMTMRUSMRK+9EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsightPR NewswireDelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs,...
- 9mo agoLTRNLantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026Business WireLantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, today announced that CEO and President Panna Sharma
- 10mo agoLTRNLantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma CompaniesBusiness WireThe A.I. Center of Excellence is planned to be based in Bengaluru and focus on large scale data-engineering, development and refinement of state-of-the-art ML-ready disease models and integration with global biopharma
- 11mo agoLTRNLantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 TrialsBusiness WireBiomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient tumors with an acceptable safety and tolerability profile – meeting all primary
- 12mo agoLTRNLantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business UpdatesBusiness WireTransformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch LP-184 Phase 1a clinical trial results demonstrate all primary endpoints achieved
- 1y agoLTRNLantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ETBusiness WireWebcast to be held Thursday, November 13th, 9:00 a.m.
- 1y agoLTRNLantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNTBusiness WireLantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, will both be
- 1y agoLTRNLantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.Business WireAI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific antibody therapies, validating LP-284's mechanism of action. A novel differentiated
- 1y agoLTRNLantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025Business WireLantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today
- 1y agoLTRNLantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid TumorsBusiness WireLP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both monotherapy or synergistic combinations with PARP inhibitors and immunotherapies. Clinical
- 1y agoLTRNIBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)GlobeNewswireAUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the
- 1y agoLTRNLantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer TrialBusiness WireLantern Pharma Inc. (NASDAQ:LTRN), an AI-driven clinical -stage oncology company developing targeted therapies for cancer that are being advanced using its proprietary computational biology and machine learning
- 1y agoLTRNLantern Pharma Reports Second Quarter 2025 Financial Results and Business UpdatesBusiness WireMajor milestone achieved with successful completion of enrollment for LP-184 Phase 1a clinical trial, with 65 patients enrolled across a range of solid tumors including glioblastoma (GBM); LP-184 is a potential
- 1y agoLTRNLantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) TrialBusiness WireNovel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progression GBM represents an annual market opportunity of $3 to $5 billion USD with an accelerating
- 1y agoLTRNLantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™Business WireIndustry-Leading Platform Achieves 94% Accuracy with Real-Time Machine Learning, Providing Open-Access to Critical CNS Drug Development Technology Additional Predictive, Analytic and Descriptive Modules are Planned
- 1y agoLTRNLantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300Business WireJapanese patient cohort enrollment is completed ahead of schedule at multiple clinical sites including the National Cancer Center in Tokyo The incidence rate of never-smokers with non-small cell lung cancer (NSCLC)
- 1y agoCMRXLTRNPARIS:ALTMELantern Pharma Announces Appointment of Dr. Lee Schalop to Board of DirectorsBusiness WireSeasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage